Exicure faces USD 2.50 million equity test: USD 6.7 million values Exicure stock

Published on 10/20/2026 at 13:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Nasdaq set a December 2, 2026 deadline. Exicure stock costs EUR 0.97 on October 20, with USD 6.7 million market value.

Compliance timeline and valuation

Exicure must restore USD 2.50 million in stockholders' equity by December 2, 2026.
Nasdaq granted Exicure an extension on September 10, 2026.
Exicure stock trades at EUR 0.97 at 1:15 p.m. CEST at Lang & Schwarz on October 20, 2026.

XCUR, US30205M3097, Illustration mit AI erstellt.

Exicure stock (ISIN US30205M3097) was trading at EUR 0.97 at Lang & Schwarz on October 20, 2026 at 1:15 p.m. CEST. The company faces a USD 2.50 million stockholders' equity test by December 2, 2026, after Nasdaq granted it additional time to restore compliance, according to MyChesCo on September 20, 2026.

Nasdaq deadline sets the central test

Nasdaq initially notified Exicure on June 5, 2026, that the company had fallen below the USD 2.50 million minimum stockholders' equity requirement under Listing Rule 5550(b)(1). The exchange granted an extension in a September 10, 2026 letter, but the extension did not restore compliance.

Exicure must publicly demonstrate that it satisfies the applicable equity requirement by December 2, 2026. MyChesCo reported that failure could lead to a delisting determination, while Exicure would retain the right to appeal to a Nasdaq Hearings Panel.

What does the valuation imply?

The market value gives the compliance issue a clear scale. Finance data put Exicure's market capitalization at USD 6.7 million as of October 19, 2026, while the company must meet a USD 2.50 million equity threshold. The threshold equals 37.31 percent of that market value, although market capitalization and stockholders' equity are different accounting measures.

Three dates define the timeline

The chronology is compact: Nasdaq issued the equity deficiency notice on June 5, 2026; it granted the extension on September 10, 2026; and Exicure's latest market indication stood at EUR 0.97 on October 20, 2026. The next substantiated date is December 2, 2026, when the extended compliance period ends.

Nasdaq listing remains the key risk

onvista identifies Exicure as a Nasdaq-listed biotechnology company with ticker XCUR and ISIN US30205M3097. Its market data page showed a 52-week range of USD 0.94 to USD 9.48 and a Nasdaq quote of USD 1.21 on October 19, 2026. The wide range underscores how strongly listing compliance can shape the stock's near-term narrative.

Stock indication and next date

The immediate investor question is whether Exicure can demonstrate the required equity position before the extended deadline. Exicure was trading at EUR 0.97 at Lang & Schwarz on October 20, 2026 at 1:15 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Exicure stock.